Inlyta® is a second line oral therapy that targets VEGF receptor-related renal cell abnormalities1. Inlyta® has been enlisted as subsidized medical treatment against one specific disease by the Community Care Fund2.
- Inlyta® (axitinib) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version August 2014
- Safety Net. HA Drug Formulary Management. Accessed on 8 August 2019. https://www.ha.org.hk/visitor/ha_visitor_index.asp?content_id=208076#